Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GC012F |
Synonyms | |
Therapy Description |
GC012F are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets both B-cell maturation antigen (BCMA; TNFRSF17) and CD19, potentially leading to antitumor activity (J Clin Oncol 41, 2023 (suppl 16; abstr 8005). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GC012F | GC-012F|GC 012F | CD19 Immune Cell Therapy 62 | GC012F are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets both B-cell maturation antigen (BCMA; TNFRSF17) and CD19, potentially leading to antitumor activity (J Clin Oncol 41, 2023 (suppl 16; abstr 8005). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05850234 | Phase Ib/II | GC012F | A Study of GC012F, a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma | Recruiting | USA | 0 |